According to a recent LinkedIn post from Touchlight, the company is highlighting an application note that compares its doggybone DNA (dbDNA) format with traditional plasmid DNA for in vivo protein expression using Sartorius Polyplus non‑viral delivery reagents. The post suggests that DNA architecture can influence delivery complex size, protein expression levels and durability across different tissues.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The company’s LinkedIn post indicates that dbDNA is associated with smaller delivery complexes and higher, more sustained protein expression in lung, spleen and muscle tissues, following both intravenous and intramuscular administration. For investors, these findings may imply a potential competitive advantage for Touchlight’s DNA format in non‑viral gene delivery applications, which could strengthen its positioning in next‑generation therapeutics and partnerships with delivery-platform providers.